The litigation centers on whether ARS and its leadership engaged in securities fraud or unlawful business practices. Tensions peaked on June 24, 2026, when the company revealed it missed a self-imposed July 1 deadline to secure expanded insurance coverage through CVS Caremark. This failure left the product without broader coverage for the peak summer and back-to-school allergy seasons.

Market reaction was swift and severe. Following the announcement, ARS stock plummeted $2.52 per share, closing at $8.02 on June 25, 2026—a single-day drop of nearly 24%. Investors who acquired securities during the relevant class period have until October 5, 2026, to petition the court to serve as lead plaintiff in the case brought by Pomerantz LLP.